A Barrier to Haemophilus influenzae
Preclinical studies of a Russian Hib vaccine, developed in Saint Petersburg Resarch and Development Institute of Vaccines and Sera have been completed.
Less than in one year scientists isolated a strain of Haemophilus influenzae type b with high productiveness of polysaccharide polyribosylribitolphosphate.
The first investigational batches of the new vaccine passed preclinical studies at the Federal State Unitary Institution “State Research Scientific Institute of Extra Pure Biological Drugs, Federal Biomedical Agency of Russia. Its results supported the safety and immunogenicity of the new vaccine versus a reference drug of a leading international manufacturer. The vaccine is recommended for first phases of clinical trials and further marketing authorisation of the immunobiological drug in the territory of the Russian Federation. Currently documents are being prepared for submission to the MoH RF for approval of clinical trials.
Development of the vaccine is topical and important because in this country invasive infections caused by Haemophilus influenza type b are universally incident, while Hib vaccination is only performed for categories at risk. Only one local Conjugated haemophilus influenza type b vaccine is currently approved in the Russian Federation. A new Russian HIB vaccine will help cover the unmet needs of Russian healthcare.